N. G. GOUDSOUZIAN
Atracurium is a neuromuscular blocking agent with an intermediate duration of action which has been found to be a particularly useful adjunct to anaesthesia in paediatric surgical procedures. Because such procedures are frequently of short duration, one intubating dose of atracurium may be sufficient for the whole surgical course.
EVALUATION OF POTENCY
For atracurium, as for other neuromuscular blocking agents, the determination of potency in children has been assessed using the evoked response of the adductor muscle of the thumb. This response has been evaluated either by an electromyogram (EMG) or by a recording of the force of contraction through a force displacement transducer. The method of stimulation was either the train-of-four (2 Hz, 2 s) or the single twitch at a frequency of 0.1 Hz.
The method of drug administration has varied with different clinical studies. Some have used the incremental dose technique in which repeated doses are given to the same patient (Goudsouzian etal., 1983; Goudsouzian, Liu et al., 1985) ; others have used the bolus method in which each group of patients received a different dose (Brandom, Rudd and Cook, 1983; Brandom et al., 1985) . With long-acting blocking agents, both methods yield nearly identical data (Donlon et al., 1980) , but with short-to intermediate-acting agents the incremental technique (Goudsouzian et al., 1983; et al., 1982) because the effect of the first dose partially dissipates before administration of the subsequent dose.
A summary of the reported data on atracurium is provided in table I. In studies using the incremental technique (Goudsouzian et al., 1983 , Goudsouzian, Liu et al., 1985 slightly higher values (ug kg" 1 ) were reported for infants and adolescents than in studies using the bolus technique (Brandom, Rudd and Cook, 1983; Brandom et al., 1985) . In children, however, no apparent difference was found. Variations in patient group data may be related to patient selection or differences in the technique of evaluation (Goudsouzian, Liu and colleagues used the twitch tension method and Brandom and colleagues used the EMG method). Table I also shows the enhancement of atracurium-induced neuromuscular blockade that is observed in children receiving halothane or isoflurane anaesthesia.
In one study (Brandom, Rudd and Cook, 1983 ) the ED 60 and ED 90 , expressed according to body weight, were lower in infants than in children. In another study however, the mg kg" 1 dose-response curves in infants, children and adolescents were essentially superimposed (Goudsouzian, Liu et al., 1985) (fig. 1 ). When the data are evaluated according to surface area, infants appear to require less atracurium than children (table I) . This is not surprising, since infants have a large surface area relative to body weight. Brandom and colleagues (1986) have recently evaluated the pharmacokinetics of atracurium in infants and children. They found that the volume of distribution (FD area ) (mg kg" 1 ) was statistically higher in infants (176 ±9 ml kg" 1 ) than in children (152±9mgkg" 1 ), whereas Vo* rea -(ml m" 1 ) was similar in infants and children. Plasma half-lives (7j a and 7jP) tended to be shorter in infants than in children, whereas clearance tended to be more rapid in infants. Neither of these differences was statistically significant. No difference was found in pharmacokinetic parameters when children with normal hepatic and renal function were compared with those presenting for hepatic transplantation.
PHARMACOKINETIC DATA

EVALUATION OF INTUBATING DOSES OF ATRACURIUM
Although dose-response studies provide valuable information on the potency of neuromuscular blocking drugs, clinicians may be more interested in other practical matters. It is more important, therefore, to determine the intubating dose of a blocking agent, evaluate conditions of intubation and determine the clinically relevant duration of action. In general, 2 or 2.5 times the ED 86 dose of a drug is given to produce rapid and effective blockade in most patients. Because large bolus doses are required for endotracheal intubation, the systemic effects of a drug will be more readily apparent. The amount of atracurium needed for this purpose has varied between 0.3 mg kg" 1 in infants to 0.6 mg kg" 1 in children and adolescents (table II) . Such doses have provided excellent to satisfactory intubation conditions within 2 min following the administration of the drug. Excellent conditions are more often noted after the larger doses of the drug or in the presence of halogenated agents. It is interesting to observe that, during train-of-four stimulation, the contraction of the adductor of the thumb disappears faster than with single twitch rates of stimulation at 0.1 Hz. This is probably the result of faster depletion of acetylcholine reserves during the train-of-four stimulation.
In the studies cited, the period of absence of twitch response after atracurium administration has lasted from 15 min to approximately 30 min. Hence, in the clinical situation, an intubating dose should provide excellent conditions for neuromuscular blockade for such an interval, and an- (Goudsouzian, Liu and Cote, 1981) indicates that atracurium has about one-third to one-half the duration of action of tubocurarine, pancuronium or dimethyltubocurarine. The side-effects of atracurium are minimal, and at clinical doses up to 0.6 mg kg" 1 it does not significantly alter the heart rate or arterial pressure in children. In studies of adults, on the other hand, an occasional, mild transient decrease in arterial pressure was sometimes seen. Such cardiovascular effects are most probably secondary to histamine release and can be minimized by administering the drug more slowly (Scott et al., 1985) .
In adolescents (age 11-16 yr) a mild diffuse rash was noted after 0.4 mg kg" 1 in 10-15% of the subjects studied (Brandom, Rudd and Cook, 1983; Goudsouzian et al., 1983) . However, similar rashes were not observed in children. Furthermore, when the drug was given in a large dose of 0.6 mg kg" 1 in a small vein, a local histamine-like response (reddening of the vein proximal to the injection site) was observed (Nightingale and Bush, 1983) . This effect was more pronounced in adolescents (11-15 yr) than in children (63% of patients v. 41%). Its incidence was least in the youngest patients studied (1-5 yr), occurring only 20% of the time.
Recently we measured plasma histamine concentrations in halothane-anaesthetized children receiving atracurium 0.6 mg kg"
1 . Only two of 10 patients had a significant increase in plasma histamine concentration; only one of these showed a very mild decrease in arterial pressure. The other had no arterial pressure change.
ATRACURIUM BY CONTINUOUS INFUSION
The rapid degradation of atracurium in plasma by ester hydrolysis and Hofrnann elimination is well documented, as are the non-cumulative properties of atracurium. It can, therefore, be usefully administered by continuous infusion. Two reports (Brandom et al., 1985; Goudsouzian and Smith, 26S BRITISH JOURNAL OF ANAESTHESIA 1985) have recently established the feasibility of this technique in children. Infusion administration is particularly useful in paediatric surgical procedures more than 1 h in duration.
The average infusion requirement to maintain a satisfactory degree of neuromuscular relaxation (twitch height = 1-10% of control) was found to be 9 (ig kg" 1 min" 1 during nitrous oxide-oxygennarcotic anaesthesia, 7-8 ug kg" 1 min" 1 in the presence of nitrous oxide-oxygen-halothane, 6 (ig kg" 1 min" 1 with nitrous oxide-oxygenisoflurane, and 5 ug kg" 1 min" 1 with nitrous oxide-oxygen-enfiurane. These data follow the general pattern of potentiation of non-depolarizing neuromuscular blocking agents by anaesthetic agents. Here, halothane had the least potentiating effect, isoflurane a moderate effect and enflurane a more marked effect, especially after a long time interval (more than 45 min). Whether the extent of augmentation of atracurium-induced neuromuscular blockade is the same or of lesser magnitude than that observed with the long-acting blocking agents needs further evaluation. The average atracurium infusion rate requirements in children anaesthetized with nitrous oxide-oxygen-narcotic are comparable to those of adults anaesthetized with nitrous oxide-oxygen-fentanyl (D 'Hollander et al., 1983; Gargarian et al., 1984) .
CLINICAL USE OF ATRACURIUM IN CHILDREN
As mentioned above, intermediate-acting neuromuscular blocking agents have more frequent application in children than in adults because of the many short surgical procedures in children. It has been shown (table II) that an average intubating dose of atracurium 0.4 mg kg" 1 will provide adequate blockade for about 30 min, and in less than 1 h almost all the clinical neuromuscular effects are dissipated. One must, however, exert sound clinical judgement and continue to monitor the adequacy of blockade, both by observation of the clinical signs and by use of the neuromuscular monitor. The presence of 1-3 fading twitches during train-of-four stimulation is an indication of satisfactory blockade, since the twitch height is less than 20% of control in these situations. However, once the fourth twitch appears, which occurs somewhat rapidly with atracurium, the anaesthetist must make a rapid decision to administer a second dose of atracurium 0.1-0.2 mg kg" 1 because the blockade would soon be inadequate.
The data presented in table II indicate that the onset time (time from injection to maximum neuromuscular blockade) in children is longer with atracurium (about 2 min) than with suxamethonium (about 0.6 min). Consequently, the clinician should wait at least 2 min before attempting endotracheal intubation. In this regard however, children, and especially infants, tend to be more quickly intubated that adults, in whom the waiting time is somewhat further prolonged (2.0-2.5 min). Attempts to diminish onset time in adult patients by the administration of a priming dose have met with limited success (Gergis et al., 1983; Nagashima et al., 1984) . Whether this technique will be applicable in children is a matter of conjecture, since it may involve a delay in the operating theatre or in the induction area. The utility of "priming" in children may be complicated by the fact that i.v. infusions are usually started just at, or even after, the induction of anaesthesia in most of the children.
The incidence of malignant hyperthermia is greater in children than in adults (1:15000 in children v. 1:100000 in adults) (Britt, 1985) . Because one of the most important triggering agents is suxamethonium, the frequent use of a drug such as atracurium should serve to diminish the incidence of this catastrophic complication in children.
Clinicians will benefit from the fact that, with intermediate-acting blocking agents, the patient can be maintained at a lighter plane of anaesthesia during a short surgical procedure. This is especially helpful for children with "irritable airways". Such patients present in two main categories. In the child who has had a respiratory tract infection 10-20 days before the scheduled time of surgery, residual symptoms such as dry cough or mild nasal discharge may persist. Ideally, one would like to perform surgery when the patient is completely free of residual symptoms, but this may prove impossible since infection frequently recurs while the surgical condition is still pending. Other children may present for diagnostic or therapeutic bronchoscopy. These children will have respiratory symptoms because of their original lesion, and consequently are liable to cough if the depth of anaesthesia is not adequately regulated. Along-actingneuromuscular blocker or suxamethonium administered by continuous infusion has generally been used in these patients to ensure adequate operative conditions. Neither of these techniques has been entirely satisfactory because the duration of these procedures may be variable. Moreover, suxamethonium infusions are associated with several side-effects such as tachyphylaxis and phase II block. The availability of an intermediate-acting blocking drug will allow for satisfactory operative conditions, free of coughing and laryngospasm. The child may also be maintained at a light level of anaesthesia throughout the procedure and then, at the conclusion of surgery, the effect of blockade can be reversed. Because of the lighter plane of anaesthesia, the patient may be expected to awaken more quickly with his reflexes intact. Consequently, the potentially dangerous interval of uncoordinated coughing and laryngospasm will be markedly diminished.
The clinical advantage of a continuous infusion of atracurium resides in the fact that, once the infusion is discontinued, the patient is wholly recovered in an average of 30 min. This technique, however, sometimes necessitates the preparation of an extra infusion set and must, of course, be administered by a reliable constant infusion device. Further, the twitch response must be carefullymonitoredbecauseof individual variation. There is also a theoretical argument against using an intermediate-acting agent for a long procedure because it may add to the cost of the procedure. The infusion technique would be most suitable for patients with renal impairment because the effect of atracurium is, for all practical purposes, unaffected by renal dysfunction. The infusion method might also be advantageously utilized in situations in which the time of conclusion of surgery cannot be predicted with assurance.
ANTAGONISM
All studies have demonstrated that the neuromuscular effects of atracurium can be adequately antagonized with appropriate doses of neostigmine preceded by atropine, provided a very small degree of twitch response has returned (Brandom, Rudd and Cook, 1983; Brandom et al., 1985; Goudsouzian, Liu et al., 1985) . There are no studies however, to indicate the most appropriate dose of neostigmine. A smaller than usual dose may conceivably be administered because the duration of action of atracurium is relatively short. In the author's experience neostigmine 0.03 mg kg" 1 preceded by atropine 0.01 mg kg" 1 seems to be more than adequate. Whether edrophonium, because of its faster onset, is a more appropriate agent remains a matter of debate.
It has been customary in children to antagonize all neuromuscular blockade. With atracurium this seems to be unnecessary. If the twitch height has recovered and the patient demonstrates a full complement of muscle power, no reversal agents may be needed. The non-cumulative properties of atracurium imply that recovery of muscle function, once it begins, will proceed predictably and that clinical improvement will be rapidly seen. In this situation, however, sound clinical judgement and adequate monitoring are important. Four equal twitches during train-of-four stimulation is a satisfactory and easily discernible point. The attending clinician should watch for adequate respiratory movements, being careful to note any paradoxical respiratory movements or tracheal tug. The patient's facial expressions are telling signs, as are the ability to open his mouth on suctioning, and lift his leg (Mason and Betts, 1980) . The most important sign in the infant is crying.
In conclusion, atracurium is an effective neuromuscular blocking agent that can be adequately used in infants and children either by a bolus dose or by a constant infusion. The cardiovascular effects of atracurium are minimal and its neuromuscular effects predictable. For practical purposes, it can be given at the same or at slightly higher doses than in adults. Because of the inter-patient variation, however, a neuromuscular monitor is strongly recommended to guide administration of maintenance doses or to individualize constant infusion rates. At the conclusion of surgery, residual neuromuscular effects can be adequately antagonized by anticholinesterase agents.
